ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
131.743,58
-0,45%
S&P 500
5.753,57
1,52%
US Dollar vs BRL
5,73056
-0,07%
Bitcoin
88.088,90
2,35%
Brent Oil
72,525
0,95%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Neurogene Inc (NGNE)

  7. Neurogene Inc (NGNE) Notícias

NGNE

Neurogene (NGNE)

Neurogene Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NGNE
DataHoraFonteTítuloCódigoCompanhia
24/02/202509:30Business WireNeurogene to Participate in Upcoming ConferencesNASDAQ:NGNENeurogene Inc
18/11/202419:25Business WireNeurogene Reports Third Quarter 2024 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
18/11/202408:45Business WireNeurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNASDAQ:NGNENeurogene Inc
11/11/202418:01Business WireNeurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNASDAQ:NGNENeurogene Inc
04/11/202409:30Business WireNeurogene Announces Oversubscribed $200 Million Private PlacementNASDAQ:NGNENeurogene Inc
21/10/202408:30Business WireNeurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett SyndromeNASDAQ:NGNENeurogene Inc
09/08/202408:30Business WireNeurogene Reports Second Quarter 2024 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
07/08/202408:30Business WireNeurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett SyndromeNASDAQ:NGNENeurogene Inc
02/07/202408:30Business WireNeurogene to Participate in BMO Genetic Medicines SummitNASDAQ:NGNENeurogene Inc
01/07/202408:30Business WireNeurogene Announces Addition to Russell 3000® IndexNASDAQ:NGNENeurogene Inc
18/06/202410:26Business WireNeurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNASDAQ:NGNENeurogene Inc
03/06/202408:30Business WireNeurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot ProgramNASDAQ:NGNENeurogene Inc
10/05/202408:30Business WireNeurogene Reports First Quarter 2024 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
07/05/202407:19Business WireNeurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual MeetingNASDAQ:NGNENeurogene Inc
22/04/202417:36Business WireNeurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT MeetingNASDAQ:NGNENeurogene Inc
18/03/202417:14Business WireNeurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
04/03/202409:30Business WireNeurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical TrialNASDAQ:NGNENeurogene Inc
29/02/202409:30Business WireNeurogene to Participate in Upcoming Investor ConferencesNASDAQ:NGNENeurogene Inc
16/01/202409:00Business WireNeurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical OfficerNASDAQ:NGNENeurogene Inc
05/01/202409:00Business WireNeurogene Announces Business Update and 2024 OutlookNASDAQ:NGNENeurogene Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NGNE

Seu Histórico Recente

DGFX
BSTBTC
BlockStamp
COIN
RUNEEEEBTC
Rune
LATK
PAXGUSDT
Paxos Gold
EU
AEX4L
AEX X4 everage Net Return
Delayed Upgrade Clock
ADVFN Logo
Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios